LYFE Capital is a China-founded healthcare fund that has deliberately evolved from China-focused growth investing to a global private-equity style platform deploying most capital in Asia ex-China and the US, with China now representing only ~10% of its latest fund. The firm focuses narrowly on critical healthcare supply chain assets and manufacturing infrastructure rather than therapeutics, positioning itself around the thesis that geopolitical shifts will force a multi-country re-architecture of Asia's healthcare manufacturing base.